Document:

Amended and Restated Distribution Agreement dated March 1, 2005

 EXHIBIT 10.7 
  
 AMENDED AND RESTATED DISTRIBUTION AGREEMENT 
  
 This AGREEMENT is made as of March 1st 2005 (the “Effective Date”), by and between HemoSense, Inc., (hereafter referred to as “HemoSense”), a California Corporation, and Quality Assured Services, Inc.
(aka, QAS), with its principal place of business 1506 N Orange Blossom Trail, Orlando, Florida, 32804 (hereafter referred to as “Distributor”). As used in this Agreement, HemoSense and Distributor are each referred to as a
“Party” and collectively as “the Parties.” This Agreement amends, supercedes and restates in its entirety the Distribution Agreement by and between the Parties dated March 31, 2003 (the “Original
Agreement”). 
  
 WITNESSETH: 
  
 WHEREAS HemoSense manufactures products, which include instrumentation and reagents designed
for testing various blood analytes. 
  
 WHEREAS, Distributor desires to distribute
and market the devices and related test supplies subject to the conditions set forth herein. 
  
 NOW, THEREFORE, in consideration of the premises hereof and the mutual covenants and conditions hereinafter set forth and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Parties hereto, intending to be legally bound, hereby agree as follows: 
  
 ARTICLE 1 – APPOINTMENT 
  
 HemoSense
hereby appoints Distributor and Distributor hereby accepts appointment as a non-exclusive distributor of the HemoSense products listed or described on Exhibit A (the “Products”), commencing on the date that the Original Agreement
was executed by both Parties. 
  
 When new products as part of the product line
become available, HemoSense will notify Distributor and Distributor will have the right to purchase these new products from HemoSense under the terms of this Agreement. 
  
 ARTICLE 2 – TERMS OF AGREEMENT 
  

	2.1	The initial term of this Agreement commences upon the Effective Date and ends February 28, 2007 (the “Initial Term”). Upon the expiration of the Initial Term, and
each Renewal Term thereafter (if any), this Agreement shall be automatically renewed for a one-year term (each, a “Renewal Term”) unless terminated by either Party in writing and in accordance to Article 19 of the Agreement.

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 Page 1 of 15 

	2.2	No modification of this Agreement is effective or binding unless in writing and signed by the Parties. This Agreement consists of thirteen (13) pages, including exhibits.

  

	2.3	Distributor’s authority under this Agreement is limited to directly distributing the Products solely to the end-user customers within the markets and channels identified on
Exhibit B (the “Permitted Markets/Channels”) solely in the territory identified on Exhibit B (the “Territory”). 

  

	2.4	DISTRIBUTOR has no authority or right, either legal or apparent, expressed or implied, to bind HemoSense in any contractual, financial, or legal obligation.

  

	2.5	Both Parties agree to hold harmless and indemnify the other for any loss or damage sustained by the other as a direct result of their malfeasance or action which exceed their rights
or authority in this Agreement. 

  
 ARTICLE 3 – OBLIGATIONS
OF THE DISTRIBUTOR 
  

	3.1	The Distributor will develop adequate numbers of suitably qualified personnel as well as suitable equipment and infrastructure for efficient warehousing, distribution and sale, and
other services related to the Products throughout the Territory. 

  

	3.2	The Distributor will provide appropriate and professional installation and application advice (within [***] business days of delivery to its customers), follow-up services and
advice, 24-hour on-call support, insurance reimbursement services, regulatory requirements advice and guidance, technical support, training/help/support and, at their option, data management programs to purchasers of Products when so requested by
the purchaser at no charge to HemoSense. 

  

	3.4	The Distributor will inform HemoSense on a timely basis of any claims, complaints, adverse events or deficiencies concerning the Products in the Territory and shall provide
reasonable assistance to HemoSense in handling such claims and events within a 48 hour period 

  

	3.5	The Distributor will maintain stocks of all the Products at an appropriate level determined by HemoSense and Distributor having regard to the monthly sales thereof in the Territory
and will ship product to purchasers the same business day it is requested, when orders are received by 3:00 p.m. EST on normal business days. 

  

	3.6	Within three weeks of the Effective Date, the Distributor will provide HemoSense with its unit per month Product sales forecast for the six (6) month period commencing with the
first day of the month following the Effective Date (the “Initial Forecast”). The Initial Forecast will be categorically itemized by the 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 Page 2 of 15 

	 	 
various components of the Product, (i.e. projected monthly purchases of meters, strips and other INRatio disposables). By the first ( 1st ) day of the month after the Effective Date, and on the 1st day of each month
thereafter, the Distributor will provide updated twelve (6) month rolling forecasts (the “Rolling Forecast”). 

  

	3.7	Distributor shall, at its own expense, and in a manner consistent with the sales policies of HemoSense: 

  

	 	(a)	place the Product in Distributor’s catalogues as soon as possible, attend such the appropriate trade shows and display the Product in any applicable trade show that it attends;

  

	 	(b)	provide adequate contact with existing and potential customers within the Permitted Markets/Channels and Territory on a regular basis, consistent with good business practice;

  

	 	(c)	assist HemoSense in assessing customers’ requirements for the Product, including modifications and improvements thereto, in terms of quality, design, functional capability, and
other features; and 

  

	 	(d)	submit market research information, as reasonably requested by HemoSense, regarding competition and changes in the market within the Territory. 

  

	3.8	If requested by HemoSense, Distributor shall develop an annual business plan for the Product which shall include, without limitation, promotion strategy and tactics, and sales and
other marketing plans (“Business Plan”). Any such Business Plan shall be provided to HemoSense for prior review and approval, which approval shall not be unreasonably withheld. The Business Plan for the first year of this Agreement
shall be provided to HemoSense within one (1) month after the Effective Date, and no request therefore need be made by HemoSense. Thereafter, if requested, Distributor shall provide Business Plans to HemoSense for review and approval not later than
sixty (60) days before January 1 of the Calendar Year to which such Business Plan pertains. 

  
 ARTICLE 4 – OBLIGATIONS OF THE COMPANY 
  

	4.1	HemoSense will use commercially reasonable efforts to maintain stocks of all the Products at an appropriate level having regard to the monthly sales thereof in the Territory.
HemoSense will inform the Distributor of the available stock of the Products and will provide the Distributor feedback on product deliveries (e.g. order confirmation including availability of product and shipping schedules within 24 hours of receipt
of the order). 

  

	4.2	HemoSense will use good faith commercial efforts to process and ship all orders in accordance with requested delivery dates subject to availability and mutual agreement on delivery
dates. However, no Distributor purchase orders for Products are binding on HemoSense unless accepted by HemoSense in writing. 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 Page 3 of 15 

	4.3	The delivery date requested in a Distributor purchase order shall be considered the date Distributor requests shipment by HemoSense. HemoSense will determine, in its sole
discretion, the shipping origin of the Product. The shipping confirmation will be provided to the Distributor by fax and/or by e-mail. Products shipped by HemoSense under this Agreement will, at the time of shipment, have a remaining shelf life of
at least [***] ([***]) months. 

  

	4.4	HemoSense will provide to the Distributor reasonable Product support and marketing support including training in demonstration and use of the Products. HemoSense will also supply
the Distributor with price lists, literature and support materials, advertising and support of sales programs, as well as after sales service and technical support. HemoSense will establish a [***] that will be funded by [***]% of gross product
sales from HemoSense to Distributor. These funds will be utilized exclusively on marketing programs specifically for Distributor. For purposes of this Section 4.4, “Target Sales” means, for each calendar year during the term of this
Agreement, the following: 

  

			
	 Calendar Year

	  	 Target Sales

	 2005
	  	$[***]
		
	 2006
	  	$[***]
		
	 2007 (and each
 calendar year thereafter)
	  	As determined by agreement of the Parties, as necessary to provide appropriate incentives for increase sales

  
 In addition, within sixty (60) days
after the end of each calendar year during the term of this Agreement, HemoSense will determine if the gross product sales from HemoSense to Distributor exceeded the Target Sales for such calendar year. Where such Target Sales were exceeded,
HemoSense will add to the [***] an additional amount equal to [***] percent ([***]%) of the overall gross product sales from HemoSense to Distributor in the just-completed calendar year. If at such time (that is, within sixty (60) days after the end
of each calendar year during the term of this Agreement) the marketing co-op fund includes a surplus funding balance that HemoSense has not utilized, and does not reasonably anticipate utilizing, on marketing programs specifically for Distributor as
contemplated under this Section 4.4, HemoSense will issue a credit to Distributor for the surplus amount. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 Page 4 of 15 

 ARTICLE 5 – RECORD KEEPING 
  
 The Distributor shall track and record a reasonable level of traceable detail of product sold to the Distributor’s customers under this
Agreement. These records will include, but not be limited to customer name, address, Product # detail, price, lot number (for reagents) and serial number (for instruments). Distributor agrees to maintain these records during the term of the
Agreement. These records will include monthly sales tracing reports by Product, Product number, sales, and/or account or zip code that will be sent to HemoSense no later then 30 days from the end of a calendar month. These tracings are to be used to
provide commission and sales reporting to the HemoSense sales force. 
  
 The
Parties agree to meet no less than twice yearly for half to full-day reviews of their mutual business. These reviews will be conducted in alternating locations (i.e. alternating between Distributor’s offices and HemoSense’s offices).

  
 ARTICLE 6 – CONFIDENTIALITY 
  
 For the purposes of this Article 6, the term “Confidential Information” shall be
any information embodying a whole or any portion or phase of any business, scientific or technical information, design, process, procedure, formula, improvement, concept, idea, technique, know-how, market data, and accounting data which both:

  

	 	(a)	is disclosed by one Party hereto to the other; and 

  

	 	(b)	is secret, confidential, and proprietary to the disclosing Party at the time of disclosure and is marked as such 

  
 During the period this Agreement remains in effect and for a period of five (5) years
following termination thereof, each Party (except as is explicitly otherwise required, permitted or consistent with the terms hereby) shall keep confidential, shall not use for itself or the benefit of others, and shall not copy or allow to be
copied, in whole or in part, any Confidential Information disclosed to such Party by the other. 
  
 The obligations of confidentiality imposed upon the Parties by the foregoing Paragraph shall not apply with respect to any alleged Confidential Information which: 
  

	 	(a)	is known to the recipient thereof, as evidenced by said recipient’s written records, prior to receipt thereof from the other Party hereto; 

  

	 	(b)	is disclosed to said recipient after the day hereof by a third party who has the right to make such disclosure; 

  

	 	(c)	is or becomes a part of the public domain through no fault of said recipient; or 

  

	 	(d)	is independently developed by the recipient without the use of the disclosing Party’s confidential information. 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 Page 5 of 15 

 ARTICLE 7 – OWNERSHIP OF PROPOSED SERVICES AND RESULTS 
  
 Nothing herein shall, or is intended to, grant, assign, or transfer, or shall be construed
as granting, assigning, or transferring to HemoSense or Distributor any right, title, and interest of each others technical and business information, commercial practices and procedures, processes, designs and specifications, and computer software
including, without specifications, the know-how, copyright, or other intellectual property that both have developed or acquired, or shall develop to acquire in the future, in the operation of their respective business. 
  
 ARTICLE 8 – TRANSFER 
  
 This Agreement may not be assigned by either Party, except with the written consent of the
other Party hereto. This written consent will not be unreasonably withheld by either Party. Notwithstanding the forgoing, HemoSense may transfer or assign this Agreement to a successor of all or substantially all of its business or assets in
connection with a merger, asset sale or the like. This Agreement shall inure to the benefit of and be binding upon each of the Parties hereto and their respective heirs, successors, and permitted assigns. 
  
 ARTICLE 9 – WARRANTIES AND RETURNS 
  

	9.1	HemoSense shall warrant the Products provided hereunder to the end-user customers purchasing the same from Distributor as set forth in the end-user documentation that accompanies
the Product when shipped. In no event shall HemoSense be liable to Distributor for any damages caused by delay in providing a remedy under the foregoing warranty 

  

	9.2	Except as expressly provided in this Article 9 HemoSense makes, and Distributor and its customers receive, no warranties, express, statutory, implied, or otherwise with respect to
the Products, and HemoSense specifically disclaims the implied warranties of merchantability, non-infringement, and fitness for a particular purpose. 

  
 ARTICLE 10 – PRICING 
  
 The price to Distributor of the Products shall be as set forth on Exhibit D, as amended by HemoSense periodically. DISTRIBUTOR shall be given sixty (60) days’ notice
of any price increases; provided that such price increases shall in no event exceed [***] percent per year. Prices for Products added to this Agreement after the Effective Date pursuant to Article 1 shall be as agreed upon between HemoSense and
Distributor. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 Page 6 of 15 

 ARTICLE 11 – SHIPPING 
  
 HemoSense shall not be responsible to Distributor or any of the Distributor’s accounts for any loss, damage, detention, or delay in
shipment resulting from fire, strikes, lockouts, delay in manufacture, delays in transportation or delivery of materials, embargoes, insurrection of riots, civil or military authority, acts of God, acts of Distributor, or any other case beyond its
reasonable control. 
  
 All prices are F.O.B, Distributor’s single designated
shipping facility in the continental United States (the F.O.B. Point). Unless otherwise agreed to in writing in advance by HemoSense, all shipments will be made to Distributor’s office of record. HemoSense shall package the products in
accordance with accepted, standard commercial practices for a normal shipment considering the type of item involved and normal risks encountered in shipment. Risk of loss entitled to all products shall pass to Distributor at the F.O.B. Point, unless
otherwise specifically agreed to in writing by HemoSense in advance. 
  
 ARTICLE 12 – PAYMENT TERMS 
  
 All invoice balances for
products shipped are due within sixty (60) days after the date of the invoice. All prices are exclusive to any sales use, property or similar taxes, whether federal, state, local, or foreign. Any such tax imposed upon HemoSense is required to be
collected by HemoSense upon the sale or delivery of the products shall be promptly reimbursed by DISTRIBUTOR upon demand to HemoSense. 
  
 ARTICLE 13 – INDEPENDENT CONTRACTOR 
  
 In performing the services the Distributor shall be an independent contractor and not an employee or agent of HemoSense. 
  
 ARTICLE 14 – ENTIRE AGREEMENT 
  
 This Agreement sets forth the entire Agreement and understanding between the Parties with
respect to the subject matter herein and supersedes all other prior and contemporaneous agreements, understanding, representations, and warranties, whether oral or written. This Agreement may not be amended, modified, or altered or any of its
provisions waived except in writing and signed by the authorized individual of the Party against whom enforcement is sought. 
  
 ARTICLE 15 – COUNTERPARTS 
  
 This Agreement is executed in two (2) counterparts, each of which shall for all purposes be deemed an original. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 Page 7 of 15 

 ARTICLE 16 – GOVERNING LAW/JURISDICTION 
  
 All disputes arising in any matter out of or in relation to this Agreement shall be decided in accordance with the laws of the State of
Florida. 
  
 ARTICLE 17 – SAVING CLAUSE 
  
 Any provision of this Agreement, which shall be, or shall be determined to be, invalid shall
be ineffective, but such invalidity shall not affect the remaining provisions hereof. 
  
 ARTICLE 18 – ARBITRATION 
  
 Any dispute arising out of this
Agreement or with respect to the interpretation of any provision hereof shall be decided finally by arbitration held in Orlando, Florida (if initiated by HemoSense) or San Francisco, California (if initiated by Distributor) in accordance with the
rules of the American Arbitration Association applicable to commercial arbitrations. There shall be three (3) arbitrators unless both Parties agree upon one (1) arbitrator. A decision of the arbitrators shall be final and non-appealable except as
provided in the rules of commercial arbitration. Each Party shall share equally the fees and expenses of the American Arbitration Association and shall be responsible for their own legal costs. The agreement to arbitrate shall be specifically
enforceable in a court of competent jurisdiction, and any decision of the arbitrators may be entered as a judgment in and enforced by any court of competent jurisdiction. Notwithstanding the foregoing nothing in this Agreement restricts company from
obtaining injunctive relief from a court having jurisdiction. 
  
 ARTICLE 19
– TERMINATION 
  

	19.1	Either Party may terminate this Agreement upon ninety days written notice of a breach by the other Party, if the breach is not cured during that period. 

  

	19.2	At any time at least sixty (60) days prior to the expiration of this Agreement’s Initial Term or any Renewal Term thereafter, either Party may terminate this Agreement by
providing a notice of non-renewal to the other Party, which termination will take effect as of the expiration of the then-current term. 

  

	19.3	This Agreement shall be deemed automatically terminated, in whole or in part, as appropriate, if the right to sell a Product is retracted, cancelled or withdrawn by the government
authorities (or any competent agency), or if either Party to the Agreement declares bankruptcy or otherwise becomes insolvent and unable to conduct normal business operations. 

  

	19.4	Effect of Termination. 

  

	 	(a)	Accrued Obligations. Expiration or termination of this Agreement for any reason shall not release any Party hereto from any liability which, at the time of such termination,
has already accrued to the other Party or which is attributable to a period prior to such termination nor preclude either 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 Page 8 of 15 

	 	 
Party from pursuing any rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement. It is understood and
agreed that monetary damages may not be a sufficient remedy for any breach of this Agreement and that the non-breaching Party may be entitled to injunctive relief as a remedy for any such breach. Such remedy shall not be deemed to be the exclusive
remedy for any such breach of this Agreement, but shall be in addition to all other remedies available at law or in equity. 

  

	 	(b)	Inventory. Within ten (10) days after the effective date of termination of this Agreement, Distributor shall use its reasonable efforts to provide HemoSense with a complete
inventory of Product in Distributor’s possession, in transit to Distributor from HemoSense or otherwise in Distributor’s control. Upon any expiration or other termination of this Agreement, HemoSense may inspect Distributor’s Product
inventory and audit Distributor’s records. 

  

	 	(c)	Return of Materials. All trademarks, marks, trade names, patents, copyrights, designs, drawings, formulas or other data, photographs, samples, literature, and sales and
promotional aids of every kind related to the Product or provided by HemoSense shall remain the property of HemoSense. Within thirty (30) days after the effective date of termination of this Agreement, Distributor shall destroy all tangible items
bearing, containing, or contained in, any of the foregoing, in its possession or control and provide written certification of such destruction, or prepare such tangible items for shipment to HemoSense, as HemoSense may direct, at Hemosense’s
expense. Distributor shall not make or retain any copies of any Confidential Information which may have been entrusted to it. Effective upon the termination of this Agreement, Distributor shall cease to use all trademarks and trade names of
HemoSense. During the term of this Agreement and after any termination or expiration of this Agreement, HemoSense shall have the right to continue to use and disclose for any purpose, customer data and other customer information and any and all
clinical trial results, if any, and other data relating to the Product and provided by Distributor to HemoSense during the term of this Agreement. 

  

	 	(c)	Last-Time Buy. If HemoSense provides a notice of non-renewal under Section 19.2, then at any time during the period following Distributor’s receipt of HemoSense’s
notice until the termination date, Distributor may issue a last-time buy order for Products under this Agreement, provided that the requested delivery schedule for such Products shall not extend for more than ninety (90) days following the
termination date. 

  

	 	(d)	Product. Upon termination of this Agreement, Distributor shall be entitled to distribute under the terms of this Agreement all of Distributor’s then-

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 Page 9 of 15 

	 	 
existing inventory of Product, and any additional inventory delivered to Distributor under Section 19.4(c) within the ninety (90) day period following
termination, provided such inventory is of a reasonable quantity. 

  

	 	(e)	Direct Customer. Upon Distributor’s request within the first 90 days following this Agreement’s termination, HemoSense agrees to discuss in good faith with Distributor
implementing an ongoing Direct Customer Agreement which would allow Distributor to purchase Products from HemoSense solely for purposes of supplying such Products to its then-existing consumer customers of the Product (and not for purposes of
promotion or sale to any new customers). If the parties are unable to agree upon terms of an ongoing Direct Customer Agreement within [90 days] after commencing negotiations, HemoSense may discontinue such negotiations with no further obligation to
Distributor under this Section 19.4(e). 

  
 ARTICLE 20
–LIMITATION OF LIABILITY 
  
 EXCEPT FOR LIABILITY OF EITHER PARTY TO THE
OTHER ARISING OUT OF ARTICLE 6 OR LIABILITY OF DISTRIBUTOR TO HEMOSENSE FOR DISTRIBUTION OF PRODUCT OTHER THEN IS AUTHORIZED UNDER THIS AGREEMENT, IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR LOST PROFITS, COST OF PROCUREMENT OF SUBSTITUTE GOODS, OR
ANY OTHER SPECIAL, INCEDENTAL, OR CONSEQUENTIAL DAMAGES, HOWEVER CAUSED AND WHETHER BASED IN CONTRACT, TORT, (INCLUDING NEGLIGENCE), OR OTHERWISE. THE FOREGOING LIMITATIONS SHALL APPLY REGARDLESS OF WHETHER EITHER PARTY HAS BEEN ADVISED OF THE
POSSIBILITY OF SUCH DAMAGES AND NOTWITHSTANDING THE FAILURE OF THE ESSENTIAL PURPOSE OF ANY LIMITED REMEDY STATED IN THIS AGREEMENT. 
  
 ARTICLE 21 – NOTICES 
  
 All notices given pursuant to this Agreement shall be sufficient if mailed, postage pre-paid, by certified or registered mail, addressed as set forth in Exhibit C, to the
attention of: 
  

	 	(a)	if to HemoSense, Attention: Chief Executive Officer or EVP 

  

	 	(b)	if to DISTRIBUTOR, Attention: Michael Visnich 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 Page 10 of 15 

 In witness whereof, the Parties hereto have caused this Agreement to be executed by their duly authorized officer or
representative as of the date first written above. 
  

			
	 /s/ Timothy Still

	  	 /s/ Michael R. Visnich

	Name	  	Name
		
	 EVP Sales & Marketing

	  	 C.E.O.

	Title	  	Title

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 Page 11 of 15 

 Exhibit A 
  

Products 
  
 In vitro diagnostics and ancillary supplies manufactured or labeled by HemoSense. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 Page 12 of 15 

 Exhibit B 
  

Permitted Distribution Territory, Market Segments, Sales Channels 
  
 TERRITORY: 
  
 United States of America, and its territories 
  
 PERMITTED MARKETS/CHANNELS: 
  
 Distributor’s non exclusive right to sell Products under this Agreement is limited to end-user customers within the following markets and channels: 
  
 Point-Of-Care Market Segment (POC) 
 Self-Care
Market Segment (SC) and Hospitals 
 Home Health Care Market Segment 
  

The Permitted Markets/Channels specifically excludes the long-term-care market, including the following: 
  
 Free-standing-nursing-home care facilities 
 Institutional dealers long-term care market 
  
 This exclusion shall not,
however, be considered to exclude from the Permitted Markets/Channels customers of Distributor that existed under the Original Agreement as of February 28, 2005. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 Page 13 of 15 

 Exhibit C 
  

Billing and Shipping Addresses for the PARTIES 
  
 HemoSense, Inc. 
 651 River Oaks Parkway 
 San Jose, CA 95134 
  
 Quality Assured Services, Inc. 
 1506 N Orange Blossom Trail 
 Orlando, Florida 3280 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 Page 14 of 15 

 Exhibit D 
  

2004-2005 QAS Price List 
  

														
	 Supplier Prod #

	  	 Description: Product Name

	  	Invoice Cost each

	 	 	Suggested List Price

	  	 Contents

	  	 
	 0100004
	  	INRatio Professional Kit	  	$	[	***]	 	$	1,595.00	  	 1 INRatio Meter
 1 INRatio
Professional User’s Guide
 1 Quick Reference Guide
	  	 1 Power Supply
 50 Lancets
 1 Training Video

	 0100007
	  	INRatio Patient Self-Test Kit	  	$	[	***]	 	$	1,995.00	  	 1 INRatio Meter
 1 INRatio Self-Test User’s Guide
 1 Quick Reference Guide
 1 Patient Results Log
	  	 1 auto-Lancet Device
 12 Blood Lancets

1 Starter Kit
 4 AA Batteries
 1 Carrying Tote

	 0100071
	  	INRatio Test Strips - Box of 12	  	$	[	***]	 	$	120.00	  	12 Test Strips	  	 
	 0100139
	  	INRatio Test Strips - Bulk Pack of 48	  	$	[	***]	 	$	264.00	  	48 Test Strips	  	 
	 0100011
	  	Power Supply	  	$	[	***]	 	$	20.00	  	1 Power Supply (120v)	  	 
	 0200046
	  	Axiohm Printer	  	$	[	***]	 	$	350.00	  	 1 Printer
 1 Printer Cable
 1 Power Transformer
	  	 1 User’s Manual
 1 Roll of Labels

1 Spindle

	 0200009
	  	Professional VHS Video	  	$	[	***]	 	$	10.00	  	 	  	 
	 0200120
	  	Self-Test VHS Video	  	$	[	***]	 	$	10.00	  	 	  	 
	 0200133
	  	Self-Test DVD	  	$	[	***]	 	$	10.00	  	 	  	 
	 0200123
	  	INRatio Professional User’s Guide	  	$	[	***]	 	$	10.00	  	 	  	 
	 0200116
	  	INRatio Self-Test User’s Guide	  	$	[	***]	 	$	10.00	  	 	  	 
	 0200077
	  	INRatio Self-Test Healthcare Professional User’s Guide	  	$	[	***]	 	$	10.00	  	 	  	 
	 0200122
	  	12 Unilet GP Lancets (21g) for use in auto-Lancet Device	  	$	[	***]	 	$	3.50	  	 	  	 
	 0200138
	  	100 Unilet GP Lancets (21g) for use in auto-Lancet Device	  	$	[	***]	 	$	12.50	  	 	  	 
	 0200121
	  	auto-Lancet Device	  	$	[	***]	 	$	10.00	  	 	  	 
	 0200016
	  	Carrying Tote	  	$	[	***]	 	$	19.95	  	 	  	 
	 0200083
	  	Patient Results Log 3 Pack	  	$	[	***]	 	$	3.50	  	 	  	 
	 0902009
	  	50 “Unistik 2” Single Use Lancets (21g)	  	$	[	***]	 	$	10.50	  	 	  	 
	 0200235
	  	MicroSafe Capillary Tubes, 15 μL, Bag of 50	  	$	[	***]	 	$	10.00	  	 	  	 

  
 Additional Notes 
  
 HemoSense, Inc. must provide a process that assures the ability to erase prior results when
exchanging QAS owned “fleet” monitors between users. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission.INR PST Supplier Agreement dated April 2, 2004

 Exhibit 10.8 
  
 HEMOSENSE INR PST SUPPLIER AGREEMENT 
  
 This AGREEMENT made as of April 2, 2004 by and between Raytel Cardiac Services, with its principal place of business, 7
Waterside Crossing, Windsor, CT 06095 (hereafter referred to as “RCS” or “DISTRIBUTOR”), and HemoSense, Inc., with its principal place of business 600 Valley Way, Milpitas, CA 95035 (hereafter
referred to as “HemoSense” or “SUPPLIER”), a California Corporation, and referred to collectively hereafter as “the PARTIES”. 
  
 Recital: 
  
 A. HemoSense manufactures products, which include instrumentation and reagents designed for testing various blood analytes, known and referred to herein as the
“PRODUCTS” (Exhibit A, “Products”), and 
  
 B. RCS is a
provider of remote cardiac monitoring services with a recognized status of an Independent Diagnostic Testing Facility (IDTF); and 
  
 C. RCS desires to distribute and market HemoSense Products and related test supplies in conjunction with certain monitoring services it provides, subject to the
conditions set forth herein; and 
  
 NOW, THEREFORE the parties agree as
follows: 
  

	 	1.	Appointment. Hemosense hereby appoints, and RCS hereby accepts HemoSense appointment of RCS as a nonexclusive distributor of HemoSense Products as listed in Schedule
A commencing on the date that this agreement is executed. RCS’s authority under this Agreement is limited to distributing Products directly to its end-use customer patients, medical clinics, hospitals, physician groups and other medical
sites (collectively, “End Users”). RCS has no right to appoint sub-distributors. 

  

	 	2.	Products. RCS will be entitled to distribute, market and sell the HemoSense Products in the territory listed in Schedule B. HemoSense reserves the right, at
it’s sole discretion, without notice at any time, to offer, license, rent or sell HemoSense Products, directly or indirectly, through the appointment of additional distributors in the territory, however Hemosense agrees that at no time during
the term of this agreement will it enter into or maintain a distribution or co-marketing agreement with any organization that competes with RCS in the businesses of [***] or [***], or 30-day cardiac event monitoring. When new Products as part of the
Product line become available, HemoSense will notify RCS and RCS will have the right to purchase these new Products from HemoSense. At its sole discretion, HemoSense may implement changes to the Products or develop new Products. Any such changes or
developments that may affect any aspect of RCS’s distribution, or the use of these Products by RCS or it’s customers, shall be communicated to RCS at least thirty (30) days prior to the implementation of such changes or developments.
HemoSense also warrants that regardless of any such changes, HemoSense will continue to make test strips available in sufficient quantities to support RCS’s existing customer base, and such test strips will continue to available to RCS at a
price no higher than that previously agreed upon. 

  

	 	3.	Term of Agreement. This agreement will be in effect for a twelve (12) month term commencing upon the execution date of this agreement (the “Initial Period”). This
Agreement shall thereafter continue in effect upon the same terms and conditions for successive one (1) year 

 *** Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission.*** 

 

 1 

 terms, unless either Party, at least ninety (90) days prior to the end of the initial or any successive
term gives written notice to the other Party of its intention to terminate this Agreement at the conclusion of the term then in progress. During the term of this Agreement or any renewal term, this Agreement may be terminated by either Party for a
breach of this Agreement or other good cause by providing notice of such breach or good cause, and the breaching party shall then have thirty (30) days to correct the breach, and if the breach has not been corrected then the non-breaching party may
then terminate this Agreement by providing written notice of termination to the breaching party. 
  

	 	4.	Payment Terms. Payment with regard to each of the Hemosense Products shall be made in United States Dollars at the address designated by Hemosense. Payment will be by
certified check or wire transfer to a bank account designated by HemoSense. Payment will be within [***] from the date of each invoice for HemoSense Products A late fee of [***]% per month or the maximum rate permitted by usury law may be assessed
against any outstanding balance greater than [***] due HemoSense, at HemoSense’ sole discretion. 

  

	 	5.	Shipment of Products. All HemoSense Products will be shipped F.O.B. shipping point from Hemosense facility in Milpitas, CA. Risk of loss and damage to Products shall pass to
RCS upon delivery of possession of such Products to the carrier. RCS will be responsible for payment of shipping charges. Raytel agrees to pay shipping charges on all orders “drop shipped” by HemoSense directly to an end-user customer for
RCS. 

  

	 	6.	Ordering, Delivery; Inspection and Return. RCS will place written orders (“order”) for the HemoSense Products, each of which shall be (i) sent to HemoSense at the
address first written above (or such other address as HemoSense may designate), (ii) request a delivery date during this Agreement’s term. Notwithstanding anything to the contrary set forth in this Agreement, no order is binding until accepted
by HemoSense, provided that orders will be assumed to have been accepted by HemoSense if HemoSense does not notify RCS within five (5) business days after receipt of an order of its rejection of that order. Orders will not be binding until the
earlier of such acceptance or shipment, and, in the case of acceptance by shipment, only to the portion of the order actually shipped. HemoSense shall use good faith commercial efforts to process and ship all accepted orders in accordance with
requested delivery dates; provided that in no case shall HemoSense have any obligation to with respect to requested delivery dates that follow, by less than 30 days, the date of HemoSense’ receipt of RCS’s order. Upon request by RCS,
HemoSense will confirm order shipment to RCS by fax or email. RCS shall inspect the Products upon receipt and, unless RCS reports in writing to HemoSense any visible, external damages or defects within 5 business days of receipt thereof (including,
with each such notice, a written description of RCA’s reasons for rejecting the Products and a request for a return-materials-authorization (“RMA”) number from HemoSense), such HemoSense Products will be deemed accepted and RCS shall
have waived any remedies with respect to any such visible external damages. A damaged HemoSense Product properly rejected under this Section 6 will be promptly returned by RCS to HemoSense and will be replaced by HemoSense at no charge to RCS.
HemoSense will ship Products with no less than [***] months shelf life remaining on those Products for the first [***] months of our agreement, but [***] months minimum for the remainder of the agreement, to fulfill the terms of this Agreement. Any
Products purchased by RCS that remain unsold are the property of RCS. All Product orders are subject to this Agreement’s terms and conditions. Nothing contained in any 

  

 *** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. 
  

 2 

 order or like document that RCS submits to HemoSense will in any way modify or add to this
Agreement’s terms and conditions. 
  

	 	7.	Forecasting. RCS will provide a 12-month non-binding rolling forecast for HemoSense Products to HemoSense. By the 15th of the first month of each calendar quarter. 

  

	 	8.	Leasing Agreement: A master lease line will be made available through an independent leasing agent. RCS, upon approval of the lease agent, shall make monthly lease payments
according to the terms of the lease agreement negotiated between the designated lease agent and RCS. 

  

	 	a.	Consignment: RCS shall provide HemoSense with storage and warehousing services with respect to INRatio Meters that HemoSense consigns to RCS until delivery is made to an RCS
customer within the Territory. Upon shipment of the HemoSense Product to an RCS End-User customer, the consignment converts to a sale that RCS shall report to HemoSense. 

  

	 	b.	Risk of Loss: HemoSense retains all title to the consigned Products held by RCS on consignment. Consistent with Section 5, risk of loss in such consigned inventory remains
with RCS, including where RCS has been found negligent in the storage of equipment, and for loss due to theft or an act of God, until delivery of the RCS inventory from RCS to the End-User customer, at which time title shall pass directly from
HemoSense to the third party leasing agent pursuant to the terms of the master lease line agreement between RCS and the leasing agent. RCS is required to maintain insurance against the risk of loss described above. 

  

	 	c.	Notification: Concurrently with each lease Product delivery, RCS shall render an invoice for the delivered Product directly to HemoSense and the third party leasing agent.
Such invoices shall be provided to confirm the conversion of a consigned instrument to a Lease through the leasing agent. This conversion to a sale also will initiate the payment of the instruments from the leasing agent to HemoSense.

  

	 	9.	Pricing. Upon the effective date of this agreement the HemoSense Products will have the pricing detailed in Schedule A. These prices shall not change for the
initial term of this agreement. Prices may be revised upward or downward every [***] months on the agreement effective date anniversary. Any price increases, excluding third party leasing costs, shall not exceed [***]% per annum. [***] notice must
be provided by HemoSense to the RCS if there are to be any price increases. 

  

	 	10.	 Uses, Maintenance, Repair and Storage. RCS shall ensure, at RCS’s sole expense, that the HemoSense Products at RCS storage will be: (i) stored, kept in
good repair, condition and working order and is used only for the purposes, and in the manner, set forth in written manuals and instructions from HemoSense, (ii) placed by RCS with end-users / patients that will be trained in accordance with the
applicable training manual and regulatory agency requirements for the performance of INR Anticoagulation home monitoring; (iii) not altered, 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 3 

	 	 
replaced or moved to a location(s) other than the one to be agreed to in accordance to section 4 above, without written notice being provided to HemoSense
(not including placing of HemoSense Products with end-users). HemoSense shall, at any time upon reasonable prior notice to RCS, have access to the HemoSense Products Inventory held by RCS to inspect, repair, maintain such HemoSense Products, and RCS
shall grant such access to HemoSense and its designees; (iv) RCS shall maintain adequate property and damages insurance with regard to all HemoSense Products that shall be in consignment/ storage at RCS’s locations.

  

	 	11.	Compliance with Laws. HemoSense represents that all of HemoSense Products are fully compliant with all laws and regulations applicable to the HemoSense Products, including
but not limited to, that all such HemoSense Products are FDA approved. RCS represents that it shall comply with all laws and regulations applicable to the distribution of Products hereunder and to the rendering of the INR Anticoagulation remote
monitoring including without limitation all applicable regulations of the U.S. Food and Drug Administration and comparable regulatory bodies within the Territory. In the event of a Product Recall: (a) the parties shall cooperate fully with each
other in effecting any recall of the HemoSense Products including communications with customers and other purchasers or users; (b) RCS must promptly provide the location of all HemoSense Products RCS has sold, rented or holds in it’s inventory
to HemoSense; (c) HemoSense will pay for all direct costs and expenses incurred by RCS at HemoSense’s request related to any such recall process. HemoSense has informed RCS that according to the FDA approval requirements with regard to the
HemoSense Products, HemoSense is required to maintain certain information with regard to end-users of the HemoSense devices (“End-User Data”), as specified in Schedule D. RCS will make the End-User Data available to HemoSense
on the 15th of the month for the prior month placements of HemoSense equipment with patients, and professional users. In all cases other than the event of Product Recall, RCS shall only provide HemoSense Product name, catalog number, lot number and
serial number, and the associated zip code in which Products were shipped. HemoSense will use the End-User Data, for the purpose of complying with FDA compliance requirements. RCS shall not export or re-export (directly or indirectly) any HemoSense
Products or documentation or other technical data. For clarity, as between the Parties, the decision of whether to recall any Product rests solely with HemoSense. 

  

	 	12.	Warranty and Service. HemoSense Limited Warranty terms for End Users are specified in Schedule E. In no event shall HemoSense have any obligation to make
repairs, replacements or corrections required, in whole or in part, as a result or (i) normal wear and tear, (ii) accident, disaster or event of force majeure, (iii) misuse, fault or negligence of or by RCS, (iv) use of Products in a manner which
they were not intended, (v) causes external to the Products such as, but not limited to, power failure or electrical power surges or (vi) use of Products in combination with equipment or software not supplied by HemoSense. In addition to HemoSense
[***] months’ warranty, HemoSense will service the rented HemoSense devices for an additional [***] months as of the last day of the above warranty period (“Service Period”) based on Schedule A. During the Service Period
HemoSense will fix or replace, without any charge, any defect or faulty HemoSense device for End Users as set forth in, and subject to the terms of, Schedule E. RCS shall provide prompt pre- and post sales and rental service and
support for all HemoSense Products located in the territory that have been sold or rented to the End-User customer through RCS or which RCS may otherwise, from time to time, agree with HemoSense to service and support. RCS will provide necessary and
useful installation assistance and consultation on the use of HemoSense Products, timely respond to customers 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 4 

	 	 
questions concerning use of HemoSense Products, assist customers in the diagnosis and correction of problems encountered in using HemoSense Products, and
keep HemoSense reasonably apprised of the general nature of such questions and problems. HemoSense shall have available for RCS’s use a toll free telephone technical assistance help desk. This may also be utilized by End-User customers after
RCS determines that they require HemoSense assistance. 

  

	 	a.	Limitation of Warranty. The warranty under this Section 12 shall not cover: (i) damage to HemoSense Products caused in whole or in part by the breach of any term of this
Agreement, including without limitation, the unauthorized operation, storage, maintenance or repair, or (ii) any damages to or defects in HemoSense Products that could have been ascertained by RCS upon inspection of Instrument in accordance with
Section 5. EXCEPT FOR HEMOSENSE’S LIMITED WARRANTY TO END USERS (SCHEDULE E) WHICH SHALL ACCOMPANY THE PRODUCTS WHEN SHIPPED, HEMOSENSE PROVIDES NO WARRANTY, EXPRESS OR IMPLIED, AND SPECIFICALLY DISCLAIMS ANY WARRANTY OF
MERCHANTABILITY, NON-INFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE PRODUCTS. 

  

	 	b.	Limitation of Liability. HemoSense’s exclusive liability for any damaged or defective Instrument for which HemoSense is responsible under Sections 5 (to RCS) and 12 (to
End Users) is limited to the repair or replacement of the damaged or defective Instrument. 

  

	 	13.	Title. On leased HemoSense Products, title shall remain with HemoSense’s designated leasing agent the terms of the lease are fulfilled by RCS 

 

	 	14.	Trademarks, Trade Names, Logos, Patents 

  
 Use during Agreement. During the term of this Agreement, RCS is authorized by HemoSense to use the trademarks, trade names, logos, service marks and
designations HemoSense uses for HemoSense Products listed on Schedule A hereto (hereinafter collectively referred to as the “Trademarks”) solely in connection with RCS’s advertisement, promotion and distribution
of HemoSense Products in the Territory on a non-exclusive basis and for no other purpose. RCS’s use of such Trademarks shall be in accordance with HemoSense’s policies in effect from time to time, including but not limited to trademark
usage and cooperative advertising policies. RCS agrees not to attach any additional trademarks, trade names, logos, service marks or designations to any HemoSense Product. RCS further agrees not to use any HemoSense Trademark in connection with any
non-HemoSense Product. RCS will submit any sales promotion materials, sales aids, press releases or advertisements pertaining to the Product, services or HemoSense which RCS intends to use or publish in the Territory to HemoSense for approval prior
to publication. HemoSense shall be provided a minimum Seven (7) working day period to review the material. If HemoSense does not get a response from RCS within Seven (7) working days of the date upon which materials were submitted for approval,
HemoSense may proceed to use the material. 
  

	 	a.	 Copyright and Trademark Notices. RCS shall include on each HemoSense Product that it distributes, and on all containers and storage media thereof, all
trademark copyright and other notices of proprietary rights included by HemoSense on such HemoSense Product. RCS agrees not to alter, erase, deface or overprint any such notice on anything provided by HemoSense. RCS also shall include the
appropriate trademark 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 5 

	 	 
notices when referring to any HemoSense Product in advertising and promotional materials. 

  

	 	b.	RCS Does Not Acquire Proprietary Rights. RCS has paid no consideration for the use of HemoSense’s Trademarks or copyrights, and nothing contained in this Agreement shall
give RCS any right, title or interest in any of them. RCS acknowledges that HemoSense owns and retains exclusive rights to all trademarks, trade names, logos, designations, service marks, copyrights and other proprietary rights, including associated
goodwill, in or associated with HemoSense Products, and that it shall not at any time during or after this Agreement assert or claim any interest in or do anything that may adversely affect the validity of any trademark, trade name, logo,
designation, service mark or copyright belonging to or licensed to HemoSense (including, without limitation any act or assistance to any act, which may infringe or head to the infringement of any of HemoSense’s proprietary rights). Upon
expiration or termination of this Agreement, RCS shall immediately cease all display, advertising and use of all HemoSense Trademarks and shall not thereafter use, advertise or display any trademark, trade name, logo or designation which is, or any
part of which is, similar to or confusing with any trademark, trade name, logo or designation associated with any HemoSense Product. 

  

	 	c.	HemoSense usage of RCS Trademarks, Trade Names, Logos. During the term of this Agreement, HemoSense is authorized by RCS to use the trademarks, trade names, logos, service
marks and designations (“RCS Trademarks”) RCS uses for RCS Products and Services, solely in connection with HemoSense’s advertisement, promotion and distribution of HemoSense Products and the RCS Services in the Territory on a
non-exclusive basis and for no other purpose. Accordingly, the provisions of sections 9(a)-9(c) will apply to HemoSense, and HemoSense will comply with the provisions of section 9(a)-9(c) above, with regard to the RCS Trademarks.

  
 No infringement of third party proprietary
rights. HemoSense represents that to the best of HemoSense’s knowledge the HemoSense Products do not infringe any US patents and/or to the best of HemoSense’s knowledge any other third party intellectual properties. 
  

	 	15.	Confidential Information. All technical and commercial information, whether or not of a documentary nature, pertaining to the systems, operations, processes, products
(including but not limited to) monitoring service procedures, customer databases, product performance data, monitoring techniques, accounting and billing systems, software, patent applications, invention disclosures, trade secrets and know-how of
RCS or HemoSense which is disclosed or observed by either Party shall be deemed “Confidential Information” to the extent (i) such information is marked “confidential” or “proprietary” (or with some similar designation)
at the time of disclosure, or (ii) if disclosed orally, is identified as Confidential Information at the time of disclosure and confirmed as such in writing within a reasonable time thereafter. Notwithstanding the foregoing, Confidential Information
shall not include any information that: (a) is now or later becomes publicly known through no fault of the receiving party, (b) was previously known to the receiving party, as evidenced by its records, (c) is subsequently furnished to receiving
party by a third party, as a matter of right and without restrictions on disclosure, or (d) is independently developed by the receiving party, as evidenced by its records. 

  
 The Parties agree that all Confidential Information will be held in trust and confidence and will not be disclosed to third
parties without the prior written permission of, or used in any manner or for any purpose inconsistent with the interests of, or without prior written permission of the owner of such Confidential Information. However, notwithstanding anything to the
contrary in this Section 16, either party may disclose the other party’s Confidential Information to the extent it is required or 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 6 

 
requested to do so by legal process, provided that the party required to make such disclosure shall give the original discloser of the Confidential
Information prompt notice so that the original discloser may seek a protective order or other appropriate relief. If a protective order is not obtained, the party required to make the disclosure shall disclose only that portion of the Confidential
Information that its counsel advises it as being legally required to disclose. Both Parties agree to hold that their obligations under this Section 16 shall survive for three years from the termination of this Agreement. 
  

	 	16.	HemoSense Support and RCS Activities. HemoSense shall support RCS distribution and marketing efforts, by rendering assistance to RCS and RCS will undertake appropriate
marketing and training activity, as listed in Schedule F. In addition, HemoSense will use commercially reasonable efforts to inform RCS of any relevant leads for customers interested in using INR Anticoagulation home monitoring of
which it becomes aware. RCS will perform relevant activities with regard to the distribution, marketing and sale of the HemoSense Products and the INR Anticoagulation remote monitoring, including for example — the training of end-users, either
directly or indirectly by third parties. RCS will provide by the 15th of every month the information as outlined in Schedule D. 

  

	 	17.	Remedies. All rights and remedies of each of the parties to this Agreement are cumulative, and may, to the extent permitted by law, be exercised concurrently or separately,
and the exercise of any one remedy shall not be deemed to be an election of such remedy or to preclude the exercise of any other remedy (whether at law or in equity). No failure on the part of HemoSense or RCS to exercise, and no delay in
exercising, any right or remedy shall operate as a waiver thereof unless specifically waived accordingly by HemoSense or RCS in writing, nor shall any single or partial exercise by HemoSense or RCS of any right or remedy preclude any other or
further exercise thereof or the exercise of any other right or remedy. 

  

	 	18.	Other Covenants. During the term of this Agreement both Parties agree that they will not co-promote or have marketing or distribution relationships with any heart valve
manufacturer identified on Schedule G (which does not include [***]). This shall not limit however, either Party from providing it’s product or service to patients with heart valves manufactured by organizations that may compete
with [***]. 

  

	 	19.	Notices. All notices shall be in writing and delivered to the other party in person or by registered mail at the address below, or such other address as may be specified by
like notice to the other party. RCS shall notify HemoSense of any claim or proceeding involving HemoSense Products within 10 days after RCS learns of such claims or proceedings. RCS and HemoSense shall notify each other within 30 days of (i) A
change in executive Management, (ii) Any change of control or a transfer of all or substantially all of each Company’s assets. 

  

	 	20.	Termination. This Agreement maybe terminated by either party, during the Initial Period or any Subsequent Period, subject to the following prior notice period: (i) with a
[***] prior written notice if terminated by HemoSense; (ii) with a [***] prior written notice if terminated by RCS. In the event of Termination of this Agreement, RCS, unless the parties agree otherwise, shall continue to pay the third party leasing
agent for the INRatio instruments in accordance to the lease payment schedule. HemoSense is obligated to support existing RCS customers with strip supplies at the prices agreed upon in this supply agreement for a period of not less than [***]
months, and for the entire remaining lease period on any INRatio instruments leased by RCS not to exceed [***] months. 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 7 

	 	21.	Severability. If any part of this Agreement is in conflict with any statute or rule of law of any state or district in which it may be sought to be enforced, then such
provision shall be deemed null and void to the extent that it conflicts therewith, but without invalidating the remaining provisions hereof 

  

	 	22.	Entire Agreement. This Agreement and Schedules contain the entire agreement between the parties and supersedes all other understandings and agreements (written or oral)
between the parties. The Schedules to this Agreement may contain terms and conditions that are in addition to or at variance with the General Terms and Conditions set forth herein. In the event of any conflict between the General Terms and
Conditions set forth herein and any of the Schedules, the terms and conditions set forth in the Schedules shall apply. Any modification of this Agreement or Schedules shall be valid only if in writing and signed by both parties. RCS may not assign
this Agreement – or any of its rights or obligations under this Agreement - without the prior written consent of HemoSense. 

  

	 	23.	Governing Law. This Lease shall be construed in accordance with and governed by the laws of the State of New York. 

  

	 	24.	The Parties (or affiliates of the Parties) will not issue any unilateral public announcement and/or press release and/or similar communications with regard to this Agreement and/or
any other maters arising from or in connection with this Agreement, without the other party’s prior consent. 

  
 IN WITNESS WHEREOF, the parties hereto have executed this Lease as of the date first above written. 
  

									
	HemoSense: HemoSense, Inc.	 	 	 	RCS: Raytd Cardiac Services
					
	By:	 	 /s/ Dale Clendon
	 	 	 	By:	 	 /s/ Richard E. Albrecht

	 Printed Name:
	 	 Dale Clendon
	 	 	 	 Printed Name:
	 	 Richard E. Albrecht

	 Title:
	 	 VP Sales
	 	 	 	 Title:
	 	 Vice President Business Development

	 Address:
	 	 600 Valley Way
 Milpitas, CA
	 	 	 	 Address:
	 	 7 Waterside Crossing
 Windsor, CT 06095

	 Date:
	 	 4/1/04
	 	 	 	 Date:
	 	 4/1/04

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 8 

  
 SCHEDULE A

  
 HEMOSENSE PRODUCTS & PRICING

  
 Pricing for PST Kit and disposable strips are the following:

  

					
	 Product Description

	 	 Product Number

	 	 Pricing

	 Patient Self-Test Kit
	 	# 0100007	 	List $1,995.00 each
	 Includes:
	 	 	 	 
	 1 INRatio Meter
 1 Users Guide
 1 Quick Reference Guide
 1 Patient Results Log
 1 Lancet Device
	 	 #_5500240_______
  
	 	 RCS Purchase Pricing with [***] Month Warranty:
 $[***]

	 12 Sterile Blood Lancets
	 	 	 	RCS Purchase Pricing with
	 1 Starter Kit
 4 AA Batteries
 1 Carrying Tote
	 	 #_5500241______
  
	 	 [***] Month Warranty:
 $[***]
 [***] Month Lease with [***] Month
 Warranty:

	 	 	________	 	 
	 	 	 	 	[***]
	 Test Strips
 Includes:
 12 INRatio Test Strips per Box
	 	#0100071	 	 List $120.00 box
 RCS
Pricing:
  
 $[***] box of 12
strips

	 Test Strips – Bulk Pack
 Includes:
 48 INRatio Test Strips
	 	#0100139	 	 List $264.00 box
 RCS Pricing: $[***] box

  
 Other provisions with regard to supply
of HemoSense Products: 
  
 Cancellation of Deliveries.
HemoSense reserves the right to cancel any orders placed by RCS and accepted by HemoSense or to refuse shipment thereof, if RCS fails to make any payment as provided in this Agreement or otherwise agreed to by HemoSense and RCS. 
  

	 	•	 	HemoSense also reserves the right, subject to a prior [***] written notice to RCS, to discontinue the manufacture or distribution of any or all HemoSense Products. Upon receipt of
such notice, RCS will be entitled, at its sole discretion, to terminate this Agreement immediately or in a shorter period than 90 days notice. 

  

	 	•	 	All of INRatio® disposable test strips will be supplied to RCS with an the maximum available shelf life, and an Expiration Date no shorter than [***] months as of date of delivery for the first [***] months of the agreement,
but a minimum of [***] [***] for the remainder of the agreement. 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 9 

  
 SCHEDULE B

  
 Territory 
  
 RCS shall have the right to promote, distribute and sell the HemoSense Products only in the
geographic area described as follows: 
  
 Total United States
Market 
  
 It is further understood and agreed to between the parties that
HemoSense may directly or indirectly sell the HemoSense Products itself within the territory or elsewhere via electronic commerce, OEM arrangements, national or worldwide purchasing/selling organizations, or HemoSense direct sales. 
  
 Moreover, it is further understood and agreed to that HemoSense has developed or, at its sole
discretion, may develop substantially similar or substantially identical products and/or merchandise under different trade names, and HemoSense retains the right, itself or through any other party, to promote, distribute and sell products under
different trade names within any part or all of the geographic area defined above. However, Hemosense agrees that at no time during the term of this agreement will it enter into or maintain a distribution or co-marketing agreement with any
organization that competes with RCS in the businesses of transtelephonic pacemaker or ICD monitoring, 30-day cardiac event monitoring, or Holter monitoring. 
  
 RCS MUST NOT EXPORT HemoSense PRODUCTS EXPORT OUTSIDE OF THE TERRITORY. 
  

RCS has the right to sell in the Self Care Market segment only for sales to patients via the physician, as an IDTF or direct to patients on a physician prescription

  
 It is understood that existing customers utilizing
HemoSense Products will not be pursued by RCS without prior agreement with HemoSense. 
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 10 

  
 Schedule D 

 
 END-USER DATA needed for FDA Reporting and Other Data Requirements

  
 RCS will keep record of the following data with regard to each
HemoSense device: 
  

	 	•	 	HemoSense product name and catalog number 

  

	 	•	 	Lot or serial number 

  

	 	•	 	For purposes of recall, name, address and contact number for each end-user of each HemoSense device 

  
 RCS will cooperate with HemoSense to provide the FDA or other regulatory agencies with required information regarding the products or
it’s users. 
  
 RCS will collect and inform HemoSense of Market conditions,
customer issues, trade and tariff issues within the territory that reasonably may be expected to affect this agreement or the transactions contemplated. 
  
 RCS’s Inventory levels of HemoSense product by Product catalog number as of the end of the month. 
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 12 

  
 Schedule E 

 
 HemoSense LIMITED WARRANTY 
  
 Limited Warranty 
  
 HemoSense guarantees to the original purchaser that the INRatio meter is free from defects in material and workmanship for one year from the
date of purchase or, if longer, up to the warranty expiration date listed on the product packaging. Under the terms of this warranty, HemoSense will replace or repair, at no charge, any meter component with defects in material or workmanship.
Warranty Service provided under this agreement does not guarantee uninterrupted operation of the meter. To qualify for this warranty, you must fill out and send in a warranty registration card. Before returning the defective component, please obtain
a Return Material Authorization number (RMA#) from HemoSense Customer Service. 
  
 HEMOSENSE MAKES NO WARRANTIES OTHER THAN EXPRESSLY STATED HEREIN AND EXPRESSLY EXCLUDES ANY IMPLIED WARRANTY OR MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE. 
  
 In addition to the batteries, the INRatio meter has only two user serviceable parts: the cleaning door and the battery door. Unauthorized
modification, abuse, or use for purposes other than expressly described herein of any other component will void the warranty. The warranty does not apply to any component that is damaged by improper storage, accident, failure to follow operating
instructions as described in the User’s Manual, or that is subject to alteration, misuse, tampering, and/or abuse. 
  
 HemoSense’s entire liability in connection with the purchase or operation of the INRatio system, including without limitation, liability arising from
Hemosense’s negligent or other acts or omissions, and/or any warranty, regardless of the legal or equitable basis of any claim, shall be limited to the price of the meter. In no event shall HemoSense be liable to the purchaser for any
incidental, indirect, special, consequential (including, but not limited to loss of income or profits), or punitive loss or damages arising from or in any way connected with the purchase or operation of the system, or any liability relating to a
claim made against a customer by a third party, even if HemoSense or its distributors are aware of the possibility of such claim or damages, except as expressly and specifically set forth pursuant to the above warranty. 
  
 Use of the INRatio system 
  
 The INRatio system is designed for use in monitoring patients on oral anticoagulant therapy. Proper adherence to the instructions in the
User’s Manual and package insert are critical to proper operation. Failure to comply with these instructions could lead to inaccurate results and resultant incorrect medication dosing. 
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 13 

  
 Schedule F 

 
 HemoSense Assistance and Support to RCS & RCS Obligations

  

	•	 	Training Material 

  

	•	 	Samples of devices — HemoSense agrees to supply up to [***] INRatio at [***]% of the price listed on Schedule A. These may be a combination of new and rebuilt units. In
addition, HemoSense will provide [***] test strip samples for use by the RCS sales force at the discretion of the designated HemoSense Regional Business Manager 

  

	•	 	Marketing and educational material 

  

	•	 	Literature for RCS sales Reps 

  

	•	 	Help Desk for end-user patients support 

  

	•	 	Sales and Marketing support, including but not limited to: 

  

	 	•	 	[***] 

  

	 	•	 	Periodic advertising support to be determined 

  

	 	•	 	Sales Compensation support for the first [***] months of this agreement at the rate of $[***] per INRatio instrument placed with an end user. This support shall be reviewed by
both Parties at the end of [***] months and may be renewed thereafter upon mutual agreement. 

  
 RCS Obligations 
  
 RCS agrees
to ensure that it’s staff is conversant with the technical language conventional to HemoSense Products and shall develop sufficient knowledge of the industry, of HemoSense Products and competitive products so as to be able to explain in detail
to it’s customers the differences and advantages of HemoSense Products. 
  
 RCS agrees to establish and maintain a separate and distinct toll-free phone number for Hemosense sales and marketing purposes. 
  
 RCS shall train and maintain a sufficient number of technical and sales personnel having the appropriate knowledge to deal with HemoSense products and provide sales
and service to customers. HemoSense shall make personnel available for training sessions to be held at the RCS’s location in order to train RCS’s personnel on sales, marketing and technical issues. 
  
 The parties agree to review the results of this agreement within 3 weeks after the first
six months, and to establish a non-binding goal for meters and strips for the second six-month period. 
  
 RCS agrees to include HemoSense in it’s marketing efforts and provide literature referring to the product line 
  
 RCS has a help desk that supports patients who will use the HemoSense INRatio system 
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}]]